In resting platelets, the GPb-IX complex, the receptor for the von Willebrand factor (vWF), is linked t o underlying actin filaments by actin-binding protein . Thrombin stimulation of human platelets leads t o a decrease in the surface expression of the GPb-IX complex, which is redistributed from the platelet surface into the open canalicular system (OCS). Because the centralization of GPlb-IX is inhibited by cytochalasin, it is believed t o be linked t o actin cytoskeletal rearrangements that take place during platelet activation. We have further characterized the mechanism of GPb-IX centralization in platelets in suspension. Following thrombin stimulation, GPb-IX shifts from the membrane skeleton of the resting cell to the cytoskeleton of the activated cell in a reaction sensitive t o cytochalasin B. The cytoskeletal association of GPIb-IX involves ABP-280, as it correlates with the incorporation of ABP-280 into the activated cytoskeleton and because no dissociation of the ABP-2801 GPIb-IX complexes is detected after thrombin activation. However, the incorporation of GPlb-IX into the cytoskeleton is complete within 1 minute, whereas GPlb-IX centralization requires 5 t o 10 minutes for completion. The movement of GPIb-IX to the cytoskeleton of activated platelets is therefore HE GPIb-IX COMPLEX (GPIb-IX), the platelet receptor for the von Willebrand factor (vWF), is a heterotrimeric complex of three polypeptides: GPIba, GPIbO, and GPIX.' The resting platelet has -25,000 to 30,000 copies of the GPIb-IX complex, most dispersed over its surface, except for a small pool localized to the open canalicular system (OCS).' Platelet activation results in dynamic redistribution of GPIb-IX and several other cell surface receptors. Shortly after stimulation, the surface expression of P-selectin' and GPIIb-IIIa' increase as a result of a-granule fusion with the plasma membrane. In marked contrast to the upregulation of these receptors, a progressive removal of GPIb-IX occurs later in the activation p r o~e s s .~.~ Clearance of GPIb-IX is through its aggregation or centralization in the plane of the cell membrane, a process similar in many aspects to the capping of receptors observed in other cells, although receptor cross-linking is unnecessary. In a cell suspension, The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.
necessary, but not sufficient for GPlb-IX centralization. Blockage of cytosolic calcium increases induced by thrombin by loading with the cell permeant calcium chelator Quin-2 AM inhibited GPb-IX centralization by 70%. but did not prevent its association with the activated cytoskeleton. Quin-2 loading did, however, decrease the incorporation of myosin II into the activated cytoskeleton. The role of myosin II was further probed using the myosin light chain kinase (MLCK) inhibitor wortmannin. Wortmannin prevents myosin II association to the activated cytoskeleton and inhibits GPb-IX centralization by 5096, without affecting actin assembly or the association of GPb-IX to the cytoskeleton. Only micromolar concentrations of wortmannin, high enough to inhibit MLCK, prevent GPlb-IX centralization. These results indicate that thrombin-induced GPlb-IX centralization requires a minimum of t w o steps, one associating GPlb-IX t o the activated cytoskeleton and the second requiring myosin II activation. The involvement of myosin II implies that GPlb-IX/ABP-280 complexes, linked t o actin filaments, are pulled into the cell center, and that platelets may exert contractile tension on vWF bound to its receptor. 0 1996 by The American Society of Hematology.
once GPIb-IX has been aggregated into the center of the cell, it goes into the OCS',' and becomes inaccessible to surface labeling with antib~dies.~.' GPIb-IX centralization and removal from the cell surface is also induced by plasmin,*,' adenosine diphosphate (ADP), or collagen in whole blood,"' and by phorbol esters." In contrast to rapid platelet responses, such as actin polymerization or secretion, which are maximally achieved within 1 minute of cell activation, the kinetics of GPIb-IX centralization are distinctly slow, starting I minute after activation and becoming maximal after 5 to 10 minutes."'.'" The molecular mechanism of this redistribution has not been established, but rearrangements of the actin cytoskeleton dependent on actin assembly following thrombin activation are n e c e~s a r y .~~'~~~'~ The physiological relevance of the changes in GPIb-IX surface expression has not been established.
In the resting platelet, GPIb-IX complexes are linked to actin filaments by actin binding protein (ABP-280)'2"5 in an interaction between the cytoplasmic tail of GPIba" and the carboxyl terminus of ABP-280."." ABP-280 is a component of both the membrane skeleton, a submembranous structure that coats the cytoplasmic surface of platelet^'^.'^ and the underlying actin cytoskeleton. The membrane skeleton is a planar lattice of spectrin, actin, and integral membrane proteins, such as GPIb-IX, which is thought to help maintain the resting platelet in a discoid ~hape.".'~ The role of the actin cytoskeleton in mediating platelet shape changes has been well documented (for a review, see")). Platelet activation in response to agonists is accompanied morphologically by the rapid deployment of lamellipods and filopods filled with actin filaments.z0-22 About 40% of the total actin in resting platelets is filamentous and activation by agonists leads, within 30 to 60 seconds, to a doubling of the platelet content of F-actin. Within 1 minute, the contractile protein myosin I1 is phosphorylated by myosin light chain Blood, Vol 87, No 2 (January 15). 1996: pp 618-629
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From kinase (MLCK) in a calcium-calmodulin-dependent pathway, associates to F-a~tin,'~-*' and is capable of generating force.26 Myosin activity is required for granule centralization and for platelet retra~tion."~'~ Some of the molecular mechanisms leading to actin assembly in platelets and their relation to platelet shape changes have recently been characteri~ed.''.'~ The nucleation sites on which actin assembly takes place are filament ends generated by two mechanisms: (1) a calcium-independent uncapping of preexisting filament ends, which results in the formation of filopods, and (2) a calciumdependent fragmentation of long actin filaments into short ones, which after uncapping results in the protrusion of lamellipods.
We have now analyzed the mechanism of thrombin-induced GPIb-IX centralization and its relationship to the actin cytoskeleton. We report that GPIb-IX centralization involves two steps, (1) the association of the GPIb-IWABP-280 complexes to the activated cytoskeleton, and (2) the activation of myosin I1 and its incorporation into the activated cytoskeleton.
MATERIALS AND METHODS
Reagents. 3ZP-orthophosphoric acid, Renaissance chemiluminescence reagents and autoradiography film were purchased from New England Nuclear Corp, Boston, MA; DNAse I from Boehringer Mannheim Corp, Indianapolis, IN; leupeptin from Vega Biotechnological Inc, Tucson, AR; benzamidine, aprotinin, phenylmethylsulfonyl fluoride (PMSF), human thrombin, prostaglandin El (PGE, ), Quin-2 AM, cytochalasin B, wortmannin, phallacidin, EGTA, Triton X-100, bovine serum albumin (BSA), and miscellaneous chemical reagents from Sigma Chemical Corp, St Louis, MO; SZ2, a mouse monoclonal antibody to glycocalicin (GPIba), from Amac Inc, Westbrook, ME; fluorescein isothiocyanate (F1TC)-labeled F(ab'), fragments of goat antimouse IgG from Tago Immunologicals, BioSource International, Camarillo, CA; horseradish peroxidase-labeled goat antimouse antibodies from Kierkegaard and Perry, Gaithersburg, MD; Protein A Sepharose CL-4B, CNBr-activated Sepharose 4B and Sepharose 2B from Pharmacia-LKB, Piscitaway, NJ. A rabbit antibody to glycocalicin (GPIba) was kindly provided by Dr Joan E.B. Fox, Children's Hospital Oakland Research Institute, Oakland, CA. Monoclonal antibody (MoAb)5 and MoAbl, mouse monoclonal antibodies against human ABP-280, have been previously characteri~ed.~'."
Isolation and activation of platelets. Human platelets were purified as described previously,2' with a few modifications. Briefly, human blood was drawn from volunteers, who had not ingested aspirin for at least 10 days, into 0.1 volume of Aster-Jandl anticoagulant and centrifuged at 200g for 15 minutes. A total of 1 pmoVL PGE, was added to platelet rich plasma and the plasma was gelfiltered over a Sepharose 2B column equilibrated with platelet buffer (10 mmoVL Hepes, 145 mmom NaCI, 5 mmol/L KCI, 2 mmoVL MgCl', 0.5 mmol/L NaH2P04, 10 mmol/L glucose, 0.3% BSA, pH 7.4) at 37°C. Gel-purified platelets were allowed to rest for 60 minutes at 37°C before use. The platelet concentration, determined on a Coulter counter (Coulter Corp, Dade County, FL), was typically 2.5 to 3.0 X 108/mL. Immediately before testing, EGTA was added to a final concentration of 2.5 mmoVL. Platelets were activated by the addition of 1 unit of thrombidml. In experiments using metabolic inhibitors, gel purified platelets were preincubated at 37°C with 40 pmoVL Quin-2 AM for 25 minutes, with 10 pmol/L wortmannin for 15 minutes, or with 10 pmoVL cytochalasin B for 2 minutes. These inhibitors were added to platelets from stock solutions in dimethylsulfoxide (DMSO). The final concentration of DMSO did not exceed 0.1 % in all experiments. Controls including DMSO carrier alone were included.
Flow cytornetry studies. Platelets (2 X 107/mL) were fixed by the addition of 1 volume of 4% paraformaldehyde in platelet buffer for 30 minutes at 37°C and washed twice with Hepes buffer (5 mmol/L Hepes, 140 mmol/L NaCI, pH 7.4) for 5 minutes. They were incubated for 1 hour at room temperature with SZ2, an antiglycocalicin antibody, at saturating conditions in Hepes buffer containing 0.3% BSA. Platelets were washed twice, incubated for 45 minutes at room temperature with FITC-labeled F(ab'), fragments of goat antimouse IgG at the dilutions recommended by the manufacturer, washed twice, and their fluorescence read in a Becton Dickinson FACscan (Becton Dickinson Immunocytometry Systems, San Jose, CA). The samples were gated for platelets, and aggregates were excluded based on forward-and side-scatter profiles. A total of 10, OOO events were recorded and the results were analyzed using Lysis I1 software (Becton Dickinson).
Isolation and analysis of platelet cytoskeletons. Low speed (1 5,600g) and high speed (100,OOOg) pellets of detergent-lysed platelets, corresponding to the cytoplasmic cytoskeleton and to the membrane skeleton respectively, were obtained according to published methods:' with a few modifications. Platelets were lysed by adding an equal volume of lysis buffer containing 2% Triton X-100, 100 mmoVL Tris HCI, 20 mmol/L EGTA, 5 pmoVL phallacidin, pH 7.4, supplemented with 2 mmol/L PMSF and 100 pg/mL each of leupeptin, aprotinin, and benzamidine. All subsequent steps were performed at 4°C. After 5 minutes, the lysates were spun at 15,600g for 5 minutes at 4°C in a Eppendorf Microfuge. The resulting low speed pellets were washed once in 1 0 0 mmoVL Tris, 20 mmol/L EGTA, 1% Triton X-100, 5 p m o m phallacidin, 1 mmol/L PMSF, pH 7.4, and twice in Tris-buffered saline (TBS; 10 mmoVL Tris HC1, 140 mmoVL NaCI, pH 7.4), solubilized in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) buffer in the presence of p-mercaptoethanol, and boiled for 5 minutes. The supernatant from the first 15,600g centrifugation was spun at 100,OOOg for 2.5 hours at 4°C in a Beckman ultracentrifuge. The resulting high speed pellets were washed in similar fashion to the slow speed pellets and solubilized in SDS-PAGE buffer. The soluble phase of the 100,OOOg centrifugation (platelet supernatant) was boiled in SDS-PAGE buffer. The Triton-insoluble and -soluble fractions from an equivalent number of platelets were analyzed by SDS-PAGE on 5% to 15% polyacrylamide gradient gels. For immunoblot analysis, proteins were transferred to Immobilon P membranes (Millipore Corp, Bedford, MA) according to the method of Towbin et al.33 Because GPIba stains poorly with Coomassie Blue on SDS-PAGE:' it was detected by immunoblotting using SZ2, a mouse antiglycocalicin MoAb, which recognizes the GPIba chain,34 at a 1:2000 dilution. ABP-280 was visualized using MoAbl antibody." Primary antibody binding was visualized with a horseradish peroxidase-labeled goat antimouse antibody at a 1:4OOO dilution. The immunoblots were developed according to the enhanced chemiluminescence method. The intensities of the bands of the SDS-PAGE and the Western blots were analyzed by densitometry by digitizing the gel using a flat-bed scanner and analyzing the images within the linear range using the NIH Image program.
Immunoprecipitation of GPIba. Platelets were lysed by adding an equal volume of lysis buffer, containing 2% Triton X-100, 100 mmom Tris HCI, 20 mmol/L EGTA, 5 p m o m phallacidin, pH 7.4, supplemented with 2 mmoVL PMSF and 100 pg/mL each of leupeptin, aprotinin, and benzamidine and 2 mg/mL DNAse I, to depolymerize cytoskeletal actin filaments, as described by FOX." After incubation for 30 minutes at 4"C, the lysate was centrifuged for 15 minutes at 100,OOOg. Clarified lysates were incubated for 2 hours at 4°C with Sepharose CL4B beads coupled to MoAb5 antibody, a mouse anti-ABP-280 MoAb," or with rabbit antiglycocalicin anti- Plufeletphosphorylution. Platelets isolated by two cycles of centrifugation at 800xg in the presence of 1 pmoVL PGE, were resuspended in platelet buffer at a concentration of 6 X lO*/mL and incubated for 1 hour at 37°C with 1 mCi/mL of "P orthophosphoric acid. Unbound 32P was separated from platelets by gel filtration in the presence of 1 pmoVL PGE, over a Sepharose 2B column. The platelets were allowed to rest for 1 hour at 37°C before use. The platelets were solublized in SDS-PAGE buffer and analyzed by SDS-PAGE on a 13% polyacrylamide gel. After drying, the gels were analyzed by autoradiography on a Renaissance film.
Zmmunoelectron microscopy studies. GPIb-IX on the surface of resting and activated platelets (thrombin, 1 UlmL) was labeled. Suspended cells were fixed with 1% glutaraldehyde in platelet buffer lacking added albumin for 10 minutes at 37°C. Fixed cells were attached to glass coverslips by diluting them to a concentration of 5 X lo6 cells/mL, placing 250 pL of the cell suspension in wells of a 96-well microtiter plate, each containing a polylysine-coated coverslip, and centrifuging the plate at 1,460g for 5 minutes at 20°C. After attachment of the cells, unreacted aldehydes were blocked with a l-minute wash of a solution composed of 1 mg/mL of sodium borohydride in platelet buffer. Blocking solution was removed and the cells washed into phosphate-buffered saline containing 1% bovine serum albumin (PBSISSA). The PBSlSSA wash solution was replaced with 25 pL of 10 pg/mL of affinity purified rabbit antiglycocalicin in PBSISSA for 60 minutes. This solution was removed, the coverslips washed three times with PBSISSA, and then incubated with 10 nm colloidal gold particles coated with affinity purified goat antirabbit IgG for 90 minutes. Unbound gold was removed by washing in PBS after which the IgG-gold complexes were fixed to the cell surface using 1% glutaraldehyde in PBS. The coverslips were washed in distilled water, rapidly frozen, freeze-dried, and rotary coated with 1.8 nm of platinum and 2.5 nm of carbon without rotation in a Cressington CFE-50 apparatus (Cressington, Watford, UK) .
RESULTS
GPIb-Ix/ABP-280 complexes bound to actin move from the membrane skeleton into the cytoskeleton a f e r thrombin stimulation. In response to agonist-stimulation, platelets form an activated cytoskeleton, which results from the assembly of soluble actin monomers into new filaments, and incorporation of the actin cross-linking proteins ABP-280, a-actinin, and the contractile protein myosin II.35,36 The formation of this actin cytoskeleton has been extensively studied by fractionating cells in the presence of the detergent Triton X-100 into three components: a 15,000g pellet (thereafter called the cytoskeleton); a 100,000g pellet (the membrane skeleton); and a 100,000g supernatant (soluble protein fraction)." Because GPIb-IX is linked to ABP-280 in resting platelet^,'^-^^ we determined whether GPIb-IX remains with ABP after activation and associates with the activated cytoskeleton. Platelets were lysed with Triton X-100 in the presence of 5 pmol/L phallacidin to stabilize existing actin filaments." As shown in Fig 1, the cytoskeleton of resting platelets was composed predominately of actin filaments and of small amounts of ABP-280, a-actinin, and GPIba. In agreement with previous findings," the majority of platelet ABP-280, a-actinin, and GPIba were bound to actin filaments present in the membrane skeletal fraction. Myosin 11 was also found predominately in the membrane skeletal fraction. Thrombin stimulation resulted in a marked increase in the amount of F-actin in the cytoskeletal fraction and in a shift of ABP-280, a-actinin, and GPIba from the membrane skeleton to the activated cytoskeleton. Densitometric analysis of the SDS-PAGE and immunoblots showed that -40% of these latter proteins became associated to the activated cytoskeleton as a result of thrombin activation. A large percentage of GPIb-IX remained associated with the membrane skeleton in activated platelets. Very little GPIba was soluble in either resting or activated cells, indicating it is in constant association with actin filaments.
The incorporation of GPIb-IX into the activated cytoskeleton correlates with incorporation of ABP-280, suggesting that GPIb-M and ABP-280 remain linked after thrombin activation. To confirm the stability of this association, we determined if the interaction between GPIb-IX and ABP-280 in resting platelet^'".'^.^^.^^ IS ' altered by cell activation.
GPIb-IX was immunoprecipitated from lysates of resting or activated platelets and the amount of coprecipitated ABP-280 was determined. All lysates were treated with DNAse I to depolymerize actin filaments and release the GPIb-IW ABP-280 complex.32 Figure 2 shows that comparable amounts of ABP-280 coprecipitated with GPIba in both resting and activated lysates. This was confirmed by densitometry analysis of the immunoblot, which showed the ratio of GPIba to ABP-280 to be 2 to 1 in resting and activated cells. Similar results were obtained by immunoprecipitating ABP-280 and analyzing the amount of coprecipitated GPIba (data not shown). These results indicate no detectable dissociation of the GPIb-IWABP-280 complex during thrombin stimulation.
Actin assembly is necessary, but not suflcient, for GPIb-ZX centralization. We also investigated whether the known inhibitory effect of cytochalasin B on the centralization of GPIb-IX in activated platelets correlates with the incorporation of GPIba into the activated cytoskeletal fraction (Fig  3) . Treatment of platelets with cytochalasins inhibits assembly of new actin filaments, incorporation of actin with ABP-280 into the activated cytoskeleton,3' and the surface redistribution of GPIb-IX.4,6~8,'o Figure 3 shows that 10 pmol/L cytochalasin B, which blocked GPIb-IX centralization as determined by flow cytometry (data not shown), prevented the incorporation of actin, ABP-280 and a-actinin into the cytoskeletal fraction. It did not, however, alter the movement of myosin I1 into the activated cytoskeleton, as previously shown by Carroll et aL3' Cytochalasin B treatment also decreased the incorporation of GPIba into the cytoskeletal fraction, indicating that thrombin-induced GPIb-IX centralization requires the addition of new actin filaments to the activated cytoskeleton and the association of GPIb-IX to the cytoskeleton. Although actin assembly is required for GPIb-IX centralization in activated cells, the kinetics for actin assembly and GPIb-IX centralization differ. Thrombin-induced actin assembly and cell shape change are complete in 1 at which time, GPIb-IX centralization is beginning?" as ation to the activated cytoskeleton indicates that although actin assembly initiates GPIb-IX centralization, additional processes are required to complete it. Analysis of the distribution of GPIb-IX on the cell surface by immunoelectron microscopy during thrombin-stimulation (Fig 5 and 6 ) confirmed that GPIb-IX centralization is slow relative to actin assembly. Figure 5A cells exposed to thrombin for 1 minute, at which time shape changes have taken place. When GPIb-IX receptors were labeled with anti-GPIb-IX immunogold at 1 minute, antiGPIb-IX gold bound avidly to the cell center, but failed to label an -0.5 pm zone at the cell margin (Fig 6A) . Filopods and other surface protrusions also labeled poorly with antiGPIb gold (Fig 6B) . During subsequent minutes, GPIb-IX molecules underwent a progressive aggregation to the cell center. Figure 5B shows the altered surface of a representative cell activated in suspension, 10 minutes after treatment with thrombin. The lack of anti-GPIb immunogold labeling of the cell surface demonstrates that most of the GPIb-IX complex was removed from the surface, although a small number of gold particles remain in the cell body. GPIb-IX centralization is calcium-dependent. To characterize further the mechanisms involved in GPIb-IX centralization, we investigated the role of intracellular calcium. A rapid rise in cytoplasmic calcium concentrations is one of the first responses induced by thrombin394' and remodels the resting cytoskeleton by activating actin filament severing proteins. Calcium transients also lead to the activation of myosin 11, which is regulated by phosphorylation. Calcium/ calmodulin complexes bind to and activate MLCK, which phosphorylates the myosin 20 kD light hai in.^'.^^.^^ To maintain resting intracellular calcium levels at nmoYL levels during exposure of cells to thrombin, platelets were incubated with 40 pmol/L Quin-2 AM for 30 minutes before exposure to agonist. This concentration and time of Quin-2 AM loading results in a final concentration of Quin 2 in platelets that is millimolar.2' As shown in Fig 7A , loading of platelets with Quin-2 AM diminished by 70% 5 20%, the ability of cells to centralize GPIb-IX after thrombin stimulation. Analysis of the activated cytoskeletons showed only a minor reduction in the incorporation of actin, ABP-280, and GPIba, which therefore did not account for the reduction in GPIb-IX centralization, but showed a marked decrease of the movement of myosin I1 into the activated cytoskeletal fraction (Fig 7B) .
Intracellular calcium chelation alters the morphology of activated cells, which fail to develop lamellipodial extensions and present short, abnormal filopod^.^' Quin-2 AM loading not only prevented GPIb-IX centralization, but also also changed the distribution of GPIb-IX on the platelet surface. Figure 5C shows the distribution of anti-GPIb immunogold on the surface of a representative Quin-2 AM loaded platelet, 10 minutes after exposure to agonist. GPIb-IX remained dispersed across the surface of the cell including the surface of the abnormal filopodia.
GPIb-IX centralization requires myosin I1 association to the cytoskeleton. To investigate further myosin I1 involvement of GPIb-IX centralization, we employed wortmannin, a fungal metabolite that irreversibly inhibits myosin I1 activation, by preventing phosphorylation of myosin light chain."*"' By flow cytometry, treatment of platelets with 10 pmoVL wortmannin inhibited thrombin-induced GPIb-IX centralization by 52% 2 20% (Fig 7A) . The effect of wortmannin treatment on the composition of the activated cytoskeletons was also determined (Fig 7B) . Compared with platelets activated in the absence of inhibitor, wortmannin did not affect actin assembly or the association of actin, aactinin, ABP-280, or GPIba to the activated cytoskeletons. In contrast, wortmannin decreased by 90% the incorporation of myosin I1 into the activated cytoskeletons, suggesting that myosin I1 activation and its interaction with the cytoskeleton are required for GPIb-IX centralization. The inhibitory effect of wortmannin on GPIb-IX centralization was confirmed by immunoelectron microscopy. Figure 5D shows that 10 pmoY L wortmannin did not prevent the shape changes induced by thrombin; this result was expected, as wortmannin does not For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From affect the actin assembly reaction." Surface labeling with anti-GPIb IgG-gold complex showed gold dispersed evenly across the cell bodies of platelets. However, filopods on thrombin-stimulated cells in the presence of wortmannin did not stain for GPIb-IX.
Although micromolar wortmannin irreversibly inhibits MLCK, wortmannin inhibits phosphatidylinositol 3-kinase (PI 3-K) in the nanomolar range.".49 To determine if the effect of wortmannin on GPlb-IX centralization results from an inhibition of PI 3-K andor MLCK, we determined the effects of a wortmannin dose-response on thrombin-induced GPIb-IX centralization (Fig 8A) and the composition of activated cytoskeletons (Fig 8B) . Wortmannin inhibited GPIb-IX centralization maximally at 10 pmol/L with a half-maximum of -0.3 pmol/L. consistent with the ICso of 0.3 pmol/ L for MLCK determined by Nakanashi et al? Analysis of activated cytoskeletons shows that myosin I1 incorporation was abrogated only at wortmannin doses > 1 pmol/L. Taken together, these results suggest that the effect of wortmannin on GP%-IX centralization is related to the inhibition of MLCK and not PI 3-K.
Wortmannin and Quin-2 AM inhibit myosin light chain phosphorylation. To further show that the inhibition of GPIb-IX centralization by Quin-2 AM or wortmannin is related to myosin 11, we determined whether treatment with these agents prevented the phosphorylation of myosin light chains in response to thrombin (Fig 9) . Platelets were analyzed 30 seconds following thrombin activation, corresponding to the maximal phosphorylation of pleckstrin and myosin light chain^.*^.^" Myosin light chain phosphorylation was totally blocked by wortmannin and mildly reduced by Quin-2 AM. The pattern of inhibition of myosin light chain phosphorylation in the presence of wortmannin and Quin-2 AM correlated with the levels of incorporation of myosin I1 into the cytoskeletal fractions (Fig 9) . Pleckstrin phosphorylation was not affected by Quin-2 AM and was only slightly reduced by wortmannin when assayed 30 seconds after cell activation.
DISCUSSION
After stimulating platelets with thrombin, most groups have found a reduction in the surface expression of GPIb-IX receptors,4" present on the surface of the resting cells, which results from a redistribution to the OCS.6.* There is, however, one published report to the contrary:' and we do not yet understand the basis of the experimental differences that result in GPIb-IX remaining on the activated platelet surface in this study. In our work, GPIb-IX was removed from the cell surface as determined by flow cytometry and electron microscopy. We have now characterized some aspects of the mechanism of centralization of GPIb-IX, which requires not only actin assembly, but also myosin I1 activation and association with the cytoskeleton. This suggests that GPIb-IX redistribution is a contractile event and may be employed to exert contractile tension on the substratum during platelet retraction.
GPlb-IX is stably connected to actin filaments by ABP-280: Activation of cells shifrs the GPlb-IWABP-280-actin complexes from the membrane skeleton to the newly formed activated cytoskeleton. Our results show first that the ma- jority of GPlb-IX is always connected to actin filaments. The platelet cytoskeleton has been further differentiated into two subfractions, a membrane skeleton and an actin-rich cytoskeleton, based on their differential sedimentation." In the resting platelet, GPIb-IX is found predominantly in the membrane skeleton. Following thrombin activation, a portion of the GPlb-IWABP-280 is shifted from the membrane skeleton to the activated cytoskeletons, in parallel with aactinin and myosin ll (Fig 1) . In an initial report describing the association of GPIb-IX and ABP-280, Fox" did not detect an increase in GPlba in activated cytoskeletons.
However, in a subsequent report by Zhang et al?2 GPTbB, another component of the GPIb-IX complex, was incorporated into activated cytoskeletons in a cytochalasin B sensitive-fashion. The initial failure of Fox to detect GPIb-IX association to the activated cytoskeletons was probably due to the absence of phallacidin in the lysis buffer because phallacidin stabilizes actin filaments" and prevents the disassembly of actin filaments in permeabilized platelets.'* Three lines of evidence demonstrate that the association between GPIb-IX and ABP-280 persists in activated cells and is necessary for GPIb-IX to interact with the cytoskeleton. First, the integrity of the GPIb-IWABP-280 complex persists after thrombin activation, as demonstrated by co- precipitation experiments (Fig 3) . Second, GPlb-IX association, or lack of association to activated cytoskeletons in cytochalasin B-treated cells, correlates with incorporation of ABP-280. Third, the absence of ABP-280 degradation products coprecipitating with GPIba indicates that calpain cleavage of ABP-2803".32 does not occur during GPIb-IX centralization. Calpain activation is unlikely to take place under the nonaggregating conditions used to follow GPIb-IX centralization, as it requires GPIIb-IIIa occupancy by fibrinogen."
The connection of GPIb-IX to actin is essential for its centralization. New actin filament assembly is also required, as cytochalasin B treatment prevents GPIb-IX centralization and the shift of GPlba to the cytoskeletons. However, a second step in addition to actin assembly is necessary to centralize GPIb-IX on the platelet surface. While actin assembly and GPIba association to the activated cytoskeletons was complete within a minute, GPlb-IX centralization reached a maximum only 5 to 10 minutes following activation, suggesting that additional processes are involved in the centralization. This second step is presumably also linked to cytoskeletal rearrangements because it only occurs after GPIb-IX becomes linked to the cytoskeleton.
Role of calcium metabolism in GPIb-IX centralization.
The marked inhibition of GPIb-IX centralization by Quin 2 indicates that it is dependent on a transient increase in intracellular calcium. Processes mediated by calcium transients include myosin I1 activation2".'"." and regulation of actin assembly," and our results suggest that both are required for optimal GPIbAX centralization. The inhibition of myosin I1 activation in the presence of Quin-2 AM was demonstrated by a decrease in the extent of phosphorylation of myosin light chain and by a parallel reduction in the amount of myosin 11 incorporated into the activated cytoskeleta1 fraction.
Quin-2 AM treatment of platelets reduced not only the degree of GPIb-IX centralization, but also affected its surface distribution. GPIb-IX remained at the periphery of the Quin-2 loaded cells and was strikingly present on the membrane periphery and the surface of filopods, structures normally devoid of GPIb-IX staining after thrombin-stimulation. An increase in intracellular calcium results in actin filament severing, presumably by gelsolin, fragmenting long actin filaments into short ones. Because the interaction of GPIb-IX with actin filaments does not change during activation, GPIb-IX/ABP-280 complexes remain attached to the underlying actin filament fragments. It is these actin filament fragments which, when uncapped, become the templates onto which the soluble actin monomers assemble and generate membrane lamellipodia and filopodia." These filament fragments would remain at the base of the extension, because they are crosslinked to the cytoskeleton. Little GPIb-IX would be expected to be on the surface overlaying the new filament portions, as all the GPIb-IX is bound to the preexisting filament fragments and little is available to be bound along the sides of the new filament portions. This hypothesis is supported by the poor GPIb-IX staining on the newly formed extensions and suggests that actin assembly indirectly restricts GPIb-IX from the cell periphery (Fig IOC) . The altered pattern of GPIb-IX staining in the presence of Quin-2 AM shows that the calcium-dependent severing of submembranous actin filaments is necessary for the spatial restriction of GPIb-IX from the new areas of filament assembly during this first phase of GPIb-IX redistribution.
Role of myosin II in GPIb-IX centralization. An important role for myosin I1 activation in GPlb-IX centralization is suggested by inhibition experiments using Quin-2 AM and wortmannin. Both of these agents interfere with the activation of MLCK, which is required for myosin I1 stimulation. As mentioned previously, Quin 2 partially inhibited myosin light chain phosphorylation and myosin 11's association with activated cytoskeletons. Wortmannin, on the other hand, completely inhibited phosphorylation of the light chain of myosin I1 and incorporation of myosin I1 into the cytoskeletal fraction. Several lines of evidence suggest that the inhibitory effect of wortmannin on GPIb-IX centralization is related specifically to its inhibition of MLCK. First, although wortmannin is also a potent inhibitor of PI 3-K, participation of PI-3 K activity in GPIb-IX centralization was ruled out by the observation that concentrations of wortmannin that completely inhibit PI 3-K do not greatly affect GPIb-IX movements on the cell surface. An effect of wortmannin on protein kinase C, which is c o n t r o~e r s i a l~~.~~ is also unlikely as pleckstrin phosphorylation was only slightly inhibited by wortmannin at these doses. Finally, wortmannin does not affect thrombin-induced actin assembly," which we For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From 
Myosin

I1
Thrombin
Myosin I1 to actinfilaments
confirmed here by evaluating the composition of activated cytoskeletons and by its lack of effect on platelet shape change (Fig 5D) .
On phosphorylation by MLCK, myosin I1 can bind actin filaments. It is likely that the shift of myosin I1 from the membrane skeleton to the activated cytoskeleton results from the binding of myosin I1 to actin filaments. This suggests that myosin I1 is linked to the membrane skeleton by an interaction with proteins other than actin filaments. Once activated, myosin I1 can exert contractile tension, which is thought to be required for platelet secretion and is necessary for clot retraction. Myosin I1 activation aggregates cytoplasmic granules preceding their fusion with the membranes of the OCS." Retraction of protrusions such as filopods occurs later in the activation process and requires actin assembly, myosin I1 activation, platelet-to-platelet contacts between fibrin polymers, and GPllb-IIIa receptors on the platelet surface." Myosin I1 filaments are believed to apply tension on actin bundles connected to GPIIb-IIIa-fibrin complexes. GPIb-IX centralization also involves the association of GPlb-IX to actin filaments, requires myosin I1 activation, and has slow kinetics. The central aggregation of GPIb-IX, therefore, appears functionally similar to the platelet retraction mediated by GPIIb-IIla receptors.
Based on our morphological and functional data, we propose the following model for GPIb-IX centralization ( Fig  IO) . In resting platelets, GPIb-IX is joined to underlying long actin filaments by ABP-280 (Fig IOA) . Thrombin acti- vation of cells leads initially to an increase in cytosolic calcium concentrations. Increased calcium activates gelsolin, which fragments the long cortical actin filaments (Fig IOB) . The actin fragments subsequently become uncapped, allowing soluble actin monomers to assemble onto their barbed ends. This shifts soluble actin, stored in complexes with P4-thymosin," into the cytoskeleton and generates membrane expansions. The surfaces of these cellular extensions are depleted of GPlb-IX complexes because the GPIb-IWABP-280 complexes have remained attached to fragmented portions of the filaments that are restricted to the previous boundaries of the resting cell (Fig IOC) . Once the activated cytoskeleton has been assembled, activated myosin 11 motors can contract actin filaments into the cell center. This process drags the actin filament-linked GPlb-IWABP-280 complexes into the cell center (Fig IOD) .
Implications ft,r the role of GPIb-IX centralization. The role of GPIb-IX centralization in platelet function has remained elusive. It was originally suggested that the decrease in surface expression of GPlb-IX following thrombin stimulation may transform platelets from a proadhesive to a proaggregatory state." However, our finding that GPIb-IX redistribution is a contractile process, analogous to that mediated by GPIlb-Ma, suggests that GPlb-IX could be also involved in linking the contractile tension generated by platelets to the substratum as they adhere and move on it. In support of this hypothesis, vWF linked to GPIb-IX is centralized along with GPIb-IX following thrombin-stimulation.s6 GPIb-IX For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From may cooperate with the GPIIb-IIIa receptor in this process. vWF is a polymeric protein that interacts with both GPIb-IX and activated GPIIb-IIIa receptors on the surface of human platelets" and can, when bound to GPIb-IX, induce activation of GPIIb-IIIa.58 Furthermore, v W F binds to fibrin, and, under high-shear stress conditions, contributes to the incorporation of platelets into clots (reviewed in"). Therefore, because vWF incorporated into clots binds potentially both GPIb-IX and GPIIb-IIIa, the generation of contractile tension between cells could involve both receptors.
